China's First AI-Designed Drug Enters Phase III Trials: MindRank's MDR-001 Makes a Surprise Move in the GLP-1 Arena

The effectiveness of AI in pharmaceuticals is gradually being confirmed, and a historic moment has recently arrived.

MindRank Announces the Official Launch of the Phase III Clinical Trial in China for MDR-001, an AI-Designed Small Molecule GLP-1 Receptor Agonist; MDR-001 Becomes the First AI-Developed Drug in China to Enter Phase III Clinical Trials.

According to the introduction, MOBILE is conducted based on MindRank's self-developed artificial intelligence-driven drug discovery platform Molecule Pro. It is a multi-center, randomized, double-blind, placebo-controlled study, planning to recruit approximately 750 overweight (24.0 kg/m²≤BMI＜28.0 kg/m²) or obese (BMI≥28.0 kg/m²) participants. The primary endpoints of the study are the percentage of weight loss from baseline at 52 weeks and the proportion of participants achieving ≥5% weight loss. Secondary endpoints include changes in waist circumference, blood lipids, blood pressure, blood glucose, quality of life scales, and inflammatory markers from baseline, with a comprehensive evaluation of the safety of long-term medication.

It is worth mentioning that Niu Zhangming, the founder and CEO of MindRank, revealed that it took only four and a half years for MindRank’s R&D pipeline MDR-001 to advance to Phase III clinical trials. Clearly, AI is breaking the "ten years to sharpen one drug" curse.

AI Drug Development Achieves Substantial Results

In the past, our understanding of the value and significance of AI pharmaceuticals was mainly based on research and predictions from some institutions.

For instance, ARK, a globally renowned investment institution, estimates that AI can reduce the cost of new drug development by 85% and shorten the development time by 40%. A report released by Boston Consulting shows that in Phase I clinical trials, the success rate of AI-generated drug molecules is as high as 80%-90%, surpassing the historical average of 50%.

Under technological upgrades, the overall industry reduces costs and increases efficiency, making the economic value highly promising. The McKinsey Global Institute (MGI) has previously estimated that generative AI could contribute billions annually to the pharmaceutical industry.Healthcare IndustryBring economic value of $60 billion to $110 billion.

However, while capital rejoices at the potential of AI in drug discovery, it is also frustrated by the pace of practice lagging far behind imagination. In this context, MindRank's ability to accelerate the advancement of AI-driven innovative drug research and deliver tangible clinical results is undoubtedly a source of excitement for the market.

According to MindRank, its technical platform Molecule Pro deeply integrates professional technologies from the fields of artificial intelligence, computational chemistry, chemistry, biology, and medicine. It is driven by deep learning, generative AI, and large models, incorporating nearly a hundred original algorithm models. Core modules such as large language model knowledge graphs and ADMET (a comprehensive method system in pharmacokinetics that studies drug absorption, distribution, metabolism, excretion, and toxicity) prediction have reached internationally leading levels.

In addition, Molecule Pro focuses on the development of drugs targeting difficult-to-drug targets. It adopts a multi-objective optimization strategy to balance activity, selectivity, pharmacokinetics, and safety. By introducing predictive mechanisms for toxicity and off-target risks, it avoids groups that may cause adverse reactions (such as structural fragments leading to liver injury). This enables precise design and optimization of molecules, thereby systematically improving the efficiency and success rate of drug development.

With the support of Molecule Pro, MindRank has built over 10 self-developed pipelines and nominated 7 clinical candidate compounds, two of which have obtained clinical trial approvals.

MDR-001, a key product of MindRank, fully utilized AI in accelerating clinical processes and ensuring quality during its development.

Caught the wave of weight-loss drugs

Aiming for "Best-in-Class," MDR-001 has demonstrated certain application potential.

It is reported that on June 19, 2025, the results of the Phase IIb clinical trial of MDR-001 were announced, which involved 317 subjects (baseline weight 90KG) after 24 weeks of treatment, demonstrating the core competitive advantage of MDR-001.

1. Significant efficacy: After 24 weeks of treatment, the weight loss reached 10.3%.

Second, it has good safety: Using a rapid titration dosing strategy of about 8 weeks, there were no drug-related serious adverse events (SAE) during the trial period. The treatment discontinuation rate due to adverse events (TEAE) was only 0.8%, and no risk of increased heart rate was observed throughout the trial.

Thirdly, comprehensive cardiovascular and metabolic improvements were observed: multiple indicators such as liver markers, waist circumference, blood pressure, blood lipids, HbA1c (glycated hemoglobin), and fasting blood glucose showed improvement. Additionally, a significant reduction in uric acid levels by up to 57.7 µmol/L (P<.00001) was achieved, along with notable improvements in various transaminase indicators. Even with the inclusion of approximately 20% of participants with prior abnormal liver function and elevated transaminase levels, there was a significant improvement in transaminase levels from baseline (with ALT levels in the high-dose group decreasing by nearly 40%).

Such clinical manifestations have also raised our expectations for the Phase III clinical study of MDR-001. If MindRank can effectively enhance the competitiveness of MDR-001 as a BIC drug, it is expected to gain a share from the growing market.

Currently, how to manage weight effectively has become a global issue. According to Frost & Sullivan data, influenced by changes in diet structure and lifestyle, the global number of overweight or obese adults has increased from 3.0674 billion in 2020 to 3.575 billion in 2024. It is projected to reach 4.0456 billion by 2029 and 4.5184 billion by 2034.

Moreover, the latest research report from The Lancet shows that by 2050, nearly 60% of adults and one-third of children worldwide will face issues of being overweight or obese.

With the explosive demand for weight loss, GLP-1 receptor agonists have gained popularity due to their comprehensive effects on lowering blood sugar, reducing weight, and protecting the cardiovascular and renal systems. MindRank has also caught up with the trend by leveraging AI. According to data from PatSnap, the global GLP-1 market size reached $35.2 billion in the first half of 2025, and it is expected to exceed $70 billion for the entire year, with an anticipated increase of over 40%.

But at the same time, it is undeniable that the GLP-1 track is gradually becoming a red ocean, with hundreds of pipelines involving GLP-1 globally. The elimination round has already begun. MindRank's AI-powered drug discovery is indeed a highlight, but the key is whether it can truly succeed. Factors such as technological maturity, financial foundation, and industry policies all play a role.

Source: Medical Research Society

       Title: The First Phase III Clinical AI-Driven Drug in China is Born! "Surprise Attack" on GLP-1, Did MindRank Take the MVP?